Johannes Czernin, MD, Editor-in-Chief of The Journal of Nuclear Medicine, has indicated that he is a founder of Sofie Biosciences and holds equity in the company and in intellectual property invented by him, patented by the University of California, and licensed to Sofie Biosciences. He is also a founder and board member of Trethera Therapeutics and holds equity in the company and in intellectual property invented by him, patented by the University of California, and licensed to Trethera Therapeutics. He also serves on the scientific advisory boards of RayzeBio, and Aktis Oncology; no other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by a guest editor.
Carolyn J. Anderson, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is on the Scientific Advisory Board of Luminphore (Berkeley, CA), and has a research contract with Earli (Redwood City, CA). She also collaborates with Cancer Targeted Technology, and her lab receives financial support in the form of a subcontract to a government small business grant from the National Cancer Institute (Bea Langton-Webster, PI). No other potential conflicts of interest were reported. Dr. Anderson is not an associate editor of manuscripts submitted to JNM with potential conflicts.
Ramsey D. Badawi, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is an investigator for Lilly. He is also an investigator for United Imaging Healthcare. He also indicated that UC Davis has a revenue sharing agreement with United Imaging Healthcare. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Henryk Barthel, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he received consulting/speaker honoraria from Hermes Medical Solutions, IBA, Lilly, Eisai and Novartis/AAA, reader honoraria from Life Molecular Imaging, and dosing committee honoraria from Pharmtrace.
Frank M. Bengel, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he receives research funding from Siemens Healthineers and from GE Healthcare. He is also on the advisory board of Abbott and Pfizer and he receives speaker honoraria from GE Healthcare, Siemens Healthineers, Curium, Pfizer and Alnylam. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Lisa Bodei, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is an unpaid consultant for AAA Novartis, Ipsen, Clovis Oncology, Curium, Great Point Partners, Point Biopharma, Rayze Bio, Fusion, Abdera, and Swiss Rocket. She also indicated that she is an unpaid speaker for AAA Novartis, Ipsen and ITM and has received research support from AAA Novartis. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Irene Buvat, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is an unpaid consultant for Siemens Healthineers and GE Healthcare. She has received research support from Siemens Healthineers and GE Healthcare. She also indicated that she receives research support from the European Commission (H2020 programs), from INCA (French Institute of Cancer), and from ANR (French Research Agency). No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Jeremie Calais, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he receives grant support from Lantheus, Novartis, and POINT biopharma, to his institution. He also reports consulting activities (speaker, blinded reader and the advisory boards) for Advanced Accelerator Applications, Amgen, Astellas, Bayer, Blue Earth Diagnostics Inc., Curium Pharma, DS Pharma, Fibrogen, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Monrol, Lantheus Lightpointmedical, Novartis, Pfizer, POINT biopharma, Progenics, Radiomedix, Sanofi, Siemens-Varian, SOFIE, Telix Pharmaceuticals, outside of the submitted work. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Alexander Drzezga, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has received research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, Sofie, Eisai, Novartis/AAA and Ariceum Therapeutics. He serves on medical advisory boards and receives speaker honoraria from Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis/AAA, Bayer Vital, Lilly. He also indicated that he holds stock from Siemens Healthineers, Lantheus Holding, Structured therapeutics, Lilly and shares in a patent for 18F-PSMA7 (18F-JK-PSMA- 7 (Patent No.: EP3765097A1; Date of patent: Jan. 20, 2021). Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Jan Grimm, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he obtained research funding from TargImmune (Basel). He is a recipient of funding from the NIH. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Ken Herrmann, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has received consultant fees from Advanced Accelerator Applications, a Novartis company, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent, Curium, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, Molecular Partners, NVision, POINT Biopharma, Pfizer, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, Sofie Biosciences, Telix, and Theragnostics, and y-mAbs. He also indicated that he has research grants from Advanced Accelerator Applications, a Novartis company, Boston Scientific, Janssen, and holds stock or other ownership interests in AdvanCell, Aktis Oncology, Convergent, NVision, Pharma 15, and Sofie Biosciences. No other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Thomas A. Hope, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that serves on advisory boards or is a consultant for AdvanCell, Bayer, Blue Earth Diagnostics, Cardinal Health, Curium, ITM, Ipsen and Lantheus. He also receives research support or participates in clinical trials from GE Healthcare, Janssen, Lantheus, Novartis, Philips, and Telix. He also holds equity in Curium. No other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Hossein Jadvar, MD, PhD, MPH, MBA, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a member of the advisory boards of Radiomedix and Pharmalogic. He is a member of the speaker’s bureau for Lantheus, and Blue Earth Diagnostics. He is a consultant to Telix and Siemens Healthcare and an investigator with Bayer. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Lale Kostakoglu, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that she is a consultant for Roche and Genentech. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Jason S. Lewis PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he receives research support from Clarity Pharmaceuticals, Avid Radiopharmaceuticals has acted as an adviser of Boxer, Clarity Pharmaceuticals, Curie Therapeutics Inc, Earli Inc, Evergreen Theragnostics, NexTech Invest, Telix Pharmaceuticals, Alpha-9 Oncology, INHIBRx, Precirix, Solve Therapeutics, Inc. and TPG Capital, is a co-inventor on technologies licensed to Diaprost, Elucida Oncology, Theragnostics, Ltd., CheMatech and Samus Therapeutics LLC, and is the co-founder of pHLIP Inc., and holds equity in Curie Therapeutics Inc, Summit Biomedical Imaging, Telix Pharmaceuticals and Evergreen Theragnostics. No other potential conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
David A. Mankoff, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is a meeting participant/lecturer for Philips Medical. He is on advisory boards and receives compensation from GE Healthcare, Reflexion Medical, ImaginAb, and Blue Earth Diagnostics. He also has an investment interest from ImaginAb and ownership in Trevarx. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Heinrich Schelbert, MD, PhD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has no potential conflicts of interest to report.
Heiko Schoder, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he has no potential conflicts of interest to report.
Barry A. Siegel, MD, Consulting Editor of The Journal of Nuclear Medicine, has indicated that he is a consultant for Capella Imaging, LLC, Curium Pharma, GE Healthcare Worldwide and Lantheus Medical Imaging, Inc. He also received clinical trial support from Blue Earth Diagnostics, Curium Pharma and Lantheus Medical Imaging. His spouse has received lecture honoraria from Siemens Healthineers. He and his spouse are accreditation reviewers for the American College of Radiology. No other potential conflicts of interest were reported.
Wolfgang Weber, MD, Associate Editor of The Journal of Nuclear Medicine, has indicated that he is on the advisory boards and receives compensation from Blue Earth Diagnostics, ITM and Pentixapharm. He has received research support from Blue Earth Diagnostics, Novartis, Roche Diagnostics, and Siemens Healthineers. No other conflicts of interest were reported. Manuscripts submitted to JNM with potential conflicts are handled by another editor.
Todd E. Peterson, PhD, Guest Editor of The Journal of Nuclear Medicine, has indicated that he has been retained as an expert by the law firm Thompson Hine relating to Thompson Hine’s representation of GE Healthcare in litigation. No other potential conflicts in interest were reported.